Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be studied again.
But then in stepped small Framingham, MA-based biotech Alzheon, led by industry veteran Dr. Martin Tolar, who saw potential in the data, and the amyloid hypothesis.
The company, which started out in earnest back in 2013 and raised $10 million last year, tweaked the drug and aimed it at a specific patient population, and after posting some encouraging early data today, is now set to enter into the precarious Phase III stage.